A

Aelis Farma SA
PAR:AELIS

Watchlist Manager
Aelis Farma SA
PAR:AELIS
Watchlist
Price: 2.88 EUR 2.13% Market Closed
Market Cap: 39.5m EUR
Have any thoughts about
Aelis Farma SA?
Write Note

Aelis Farma SA
Tax Provision

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Aelis Farma SA
Tax Provision Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Tax Provision CAGR 3Y CAGR 5Y CAGR 10Y
A
Aelis Farma SA
PAR:AELIS
Tax Provision
-€3k
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Valneva SE
PAR:VLA
Tax Provision
-€2.7m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
G
Genfit SA
PAR:GNFT
Tax Provision
-€5k
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Inventiva SA
PAR:IVA
Tax Provision
-€733k
CAGR 3-Years
-27%
CAGR 5-Years
-21%
CAGR 10-Years
N/A
Eurobio Scientific SA
PAR:ALERS
Tax Provision
-€3.3m
CAGR 3-Years
46%
CAGR 5-Years
-47%
CAGR 10-Years
N/A
OSE Immunotherapeutics SA
PAR:OSE
Tax Provision
-€3.4m
CAGR 3-Years
-44%
CAGR 5-Years
-18%
CAGR 10-Years
N/A
No Stocks Found

Aelis Farma SA
Glance View

Market Cap
35.9m EUR
Industry
Biotechnology

Aelis Farma SA develops biotechnology solutions. The company is headquartered in Bordeaux, Nouvelle-Aquitaine and currently employs 24 full-time employees. The company went IPO on 2022-02-18. The firm provides two products in clinical development, including AEF0117 for cannabis-related disorders (severe dependence, acute psychosis, and acute toxicity), and AEF0217 for cognitive deficits (disorders related to Down syndrome). The company offers viable treatments for certain pathological conditions linked to hyperactivity of the CB1 receptor, the main receptor of the endocannabinoid system. The company provides advanced drug AEF0117, to combat the harmful effects of cannabis and in particular Cannabis Use Disorders (CUD) which is the current definition of cannabis addiction in the diagnostic manual reference DSM-5. The firm operates a Research and Development (R&D) platform, which enables the Company to discover drug candidates that act as specific modulators of target receptor signaling.

AELIS Intrinsic Value
1.25 EUR
Overvaluation 57%
Intrinsic Value
Price
A

See Also

What is Aelis Farma SA's Tax Provision?
Tax Provision
-3k EUR

Based on the financial report for Dec 31, 2023, Aelis Farma SA's Tax Provision amounts to -3k EUR.

What is Aelis Farma SA's Tax Provision growth rate?
Tax Provision CAGR 1Y
-200%

Over the last year, the Tax Provision growth was -200%.

Back to Top